Abstract | BACKGROUND: OBJECTIVES: SEARCH STRATEGY: SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. MAIN RESULTS: Twelve trials were identified, but only three were prospective, randomised and controlled. A total of 94 participants were included. One demonstrated a reduction in immunological markers of disease activity and symptom scores using ketoconazole 400 mg daily for 12 months. There was no significant improvement in lung function. The other two examined the use of itraconazole for 16 weeks. In one there was a reduction in sputum eosinophils by 35% compared to 19% with placebo (p < 0.01). In the same trial, the number of exacerbations requiring oral corticosteroids was 0.4 per patient with itraconazole compared with 1.3 per patient with placebo (p < 0.03). Meta-analysis of data from both trials showed that itraconazole treated patients were more likely to have decline in serum IgE over 25% or more (Peto OR 3.30; 95% confidence intervals 1.30 to 8.15). REVIEWER'S CONCLUSIONS:
|
Authors | P A B Wark, P G Gibson, A J Wilson |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 3
Pg. CD001108
( 2003)
ISSN: 1469-493X [Electronic] England |
PMID | 12917898
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Antifungal Agents
- Itraconazole
- Ketoconazole
|
Topics |
- Antifungal Agents
(therapeutic use)
- Aspergillosis, Allergic Bronchopulmonary
(drug therapy)
- Asthma
(complications)
- Controlled Clinical Trials as Topic
- Humans
- Itraconazole
(therapeutic use)
- Ketoconazole
(therapeutic use)
|